[{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"||HMG-CoA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"||HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JW Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JW Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"||HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Digoxin","moa":"||Sodium\/potassium-transporting ATPase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"China National Center for Cardiovascular Diseases","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"||Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"China National Center for Cardiovascular Diseases","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"China National Center for Cardiovascular Diseases \/ Innovent Biologics","highestDevelopmentStatusID":"1","companyTruncated":"China National Center for Cardiovascular Diseases \/ Innovent Biologics"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"JW Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"||HMG-CoA reductase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ JW Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ JW Pharmaceutical"},{"orgOrder":0,"company":"Korea University Anam Hospital","sponsor":"Daewon Pharm. Co., Ltd | Samjin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Korea University Anam Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea University Anam Hospital \/ Daewon Pharm. Co., Ltd | Samjin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Korea University Anam Hospital \/ Daewon Pharm. Co., Ltd | Samjin Pharmaceutical"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Livalo, Pitavastatin calcium

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Livalo, Pitavastatin calcium

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

58 API Suppliers, 16 USDMF, 20 JDMF, 8 EU WC, 21 KDMF, 7 NDC API, 16 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

95 FDF Dossiers, 30 FDA Orange Book, 50 Europe, 15 Listed Dossiers

RELATED EXCIPIENT COMPANIES

5 DKSH, 2 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 1 Actylis, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 Corel Pharma Chem, 2 DFE Pharma, 5 Gangwal Chemicals, 3 Ideal Cures, 18 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 8 Microlex e.U, 1 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 2 Pluviaendo, 1 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 2 Roquette, 6 Seppic, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Sigachi Industries, 1 Silverline Chemicals, 2 The Dow Chemical Company, 1 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

39 Coating Systems & Additives, 20 Fillers, Diluents & Binders, 12 Controlled & Modified Release, 10 Lubricants & Glidants, 9 Granulation, 8 Film Formers & Plasticizers, 7 Direct Compression, 5 Empty Capsules, 5 Emulsifying Agents, 5 Thickeners and Stabilizers, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Coloring Agents, 3 Co-Processed Excipients, 3 Taste Masking, 3 Solubilizers, 3 Rheology Modifiers, 2 Disintegrants & Superdisintegrants, 2 Surfactant & Foaming Agents, 1 Chewable & Orodispersible Aids, 1 Parenteral, 1 Topical

DIGITAL CONTENT

19 News #PharmaBuzz

19 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 47 Regulatory FDF Prices

MARKET PLACE

19 APIs, 1 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 JP, 10 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Alirocumab,Pravastatin,Simvastatin,Fluvastatin,Atorvastatin,Pitavastatin,Rosuvastatin Calcium

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or Hi...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

April 08, 2014

Lead Product(s) : Alirocumab,Pravastatin,Simvastatin,Fluvastatin,Atorvastatin,Pitavastatin,Rosuvastatin Calcium

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Novo Nordisk

Denmark

EPSC

Not Confirmed

03

Basilea Pharmaceutica

Switzerland

EPSC

Not Confirmed

04

Korea University Anam Hospital

Country

EPSC

Not Confirmed

05

Seoul National University Bundang Hospital

Country

EPSC

Not Confirmed

06

China National Center for Cardiovascular Diseases

Country

EPSC

Not Confirmed

07

Upsher-Smith Laboratories

U.S.A

EPSC

Not Confirmed

08

JW Pharmaceutical

Country

EPSC

Not Confirmed

09

JW Pharmaceutical

Country

EPSC

Not Confirmed

10

F. Hoffmann-La Roche

Switzerland

EPSC

Not Confirmed